Supporting Information

Polymeric Nanomedicine for Tumor-Targeted Combination Therapy to Elicit Synergistic Genotoxicity against Prostate Cancer

Qingqing Yang,[†] Yang Yang, [†] Lian Li, Wei Sun, Xi Zhu, and Yuan Huang*

Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 610041, People's Republic of China

Corresponding author

* E-mail: huangyuan0@163.com. Tel.: +86-28-85501617. Fax: +86-28-85501617.

[†] These authors contributed equally to this work.



Figure S1. Cell viability of PC-3 cells after 12 h incubation at 37 °C with different C3-C12 modified dual drug-loaded conjugates differing in 5-Fu content (equivalent to 30 μg/mL of DOX). After incubation with the formulations, the medium was replaced with fresh medium and cells were incubated for another 24 h and finally analyzed by MTT assay.



Figure S2. Release of 5-Fu from P-Fu, P-DOX-Fu and P-(G3-C12)-DOX-Fu was evaluated by incubating the conjugates at 37 °C in phosphate buffer (0.1 M, pH 7.4) and in McIlvaine's buffer (pH 6.0) containing papain (2.0 μM).



Figure S3. Inhibition of tumor spheroid growth after treatment with 5-Fu, P-Fu or P-DOX for 7 days (equivalent DOX concentration of 10 μg/mL and 5-Fu concentration of 6.2 μg/mL).



Figure S4. Histological examination of heart, liver, spleen, lung and kidney using hematoxylin and eosin (H&E) staining. The organs were harvested from mice bearing PC-3 tumors on day 21 after being administered with saline (control), 5-Fu, DOX, P-Fu, P-DOX, P-DOX-Fu or P-(G3-C12)-DOX-Fu (equivalent to 5 μg/mL of DOX and 3.1 μg/mL of 5-Fu).